GlassScriptPhysician profile
Munish K Goyal
NPI 1902845829
$4,014.70
in general payments reported to CMS, 2019-2025
15 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,883 · 2020: $161 · 2021: $894 · 2022: $211 · 2023: $48.10 · 2024: $370 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,042.36 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $534.57 | 2019-2025 | |
| Medtronic Vascular, INC. | $358.23 | 2019-2020 | |
| Abiomed | $251.13 | 2021-2024 | Impella |
| Shockwave Medical, INC | $156.06 | 2021 | |
| Inari Medical, INC. | $148.27 | 2020 | |
| Baxter Healthcare | $120.47 | 2022 | |
| Novo Nordisk INC | $107.95 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Philips North America LLC | $91.00 | 2022 | |
| Amgen INC. | $88.61 | 2019-2025 | Repatha, Repatha |
| Stryker Corporation | $34.64 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Pfizer INC. | $30.87 | 2025 | |
| Abbott Laboratories | $23.52 | 2025 | Emboshield Nav6 |
| Scpharmaceuticals INC. | $13.94 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.08 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munish Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.